Renovaro (RENB) signed a binding letter of intent to acquire Predictive Oncology (POAI), the companies said Monday.
Under the terms of the agreement, Predictive Oncology will merge into Renovaro in exchange for a newly created series of Renovaro preferred stock, Predictive Oncology said.
The company said the parties are looking to enter definitive documentation for the merger by no later than Feb. 28.
Renovaro shares were up 12% while POAI shares were due off halt at 9:50 am ET.
Price: 1.21, Change: +0.28, Percent Change: +30.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.